Drug eluting stents (DES) have drugs (eg, 1st-generation: sirolimus, paclitaxel; 2nd-generation: everolimus, ridaforolimus, zotarolimus) bonded to the metal that limit neointimal proliferation to reduce the risk of restenosis.